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Abstract
Background: Postnatal expansion of the pancreatic b-cell mass is required to maintain glucose homeostasis
immediately after birth. This b-cell expansion is regulated by multiple growth factors, including glucose, insulin,
insulin-like growth factor (IGF-1) and epidermal growth factor (EGF). These mitogens signal through several
downstream pathways (AKT, ERK, STAT3, and JNK) to regulate the survival and proliferation of b-cells. Survivin, an
oncofetal protein with both pro-proliferative and anti-apoptotic properties, is a known transcriptional target of both
IGF-1 and EGF in cancer cells. Here, we analyzed the effects of the b-cell mitogens IGF-1 and EGF on survivin
regulation in the established pancreatic b-cell model cell lines, MIN6 and INS-1 and in primary mouse islets.
Results: In pancreatic b-cells, treatment with glucose, insulin, or EGF increased survivin protein levels at early time
points. By contrast, no significant effects on survivin were observed following IGF-1 treatment. EGF-stimulated
increases in survivin protein were abrogated in the presence of downstream inhibitors of the Raf-1/MEK/ERK
pathway. EGF had no significant effect on survivin transcription however it prolonged the half-life of the survivin
protein and stabilized survivin protein levels by inhibiting surviving ubiquitination.
Conclusions: This study defines a novel mechanism of survivin regulation by EGF through the Raf-1/MEK/ERK
pathway in pancreatic b-cells, via prolongation of survivin protein half-life and inhibition of the ubiquitin-mediated
proteasomal degradation pathway. This mechanism may be important for regulating b-cell expansion after birth.
Background
Production and maintenance of the pancreatic b-cell
mass is a highly regulated process driven by four major
mechanisms that include- b-cell replication, b-cell neo-
genesis, b-cell hypertrophy and b-cell apoptosis [1,2]. In
the rodent, an exponential expansion of the pancreatic
b-cell mass begins during the final phase of gestation
and lasts through the third week after birth. Corre-
spondingly, in humans, b-cell expansion occurs during
the last trimester of pregnancy and continues through
the first few months of life [1,2]. An increase in b-cell
mass is required for insulin secretion in the mainte-
nance of metabolic homeostasis [3], both in the initial
transition to a carbohydrate-based diet following wean-
ing and throughout life thereafter [4]. The molecular
mechanisms regulating b-cell growth are mostly
unknown but are dependent on a variety of growth
factors, including glucose, insulin, insulin-like growth
factor (IGF-I), and epidermal growth factor (EGF) [5,6],
that provide mitogenic signals to the b-cell in vivo.
Epidermal growth factor receptor (EGFR) is a member
of the ErbB receptor family, consisting of 4 transmem-
b r a n et y r o s i n ek i n a s er e c e p t o r s :E G F R( E r b B 1 ,H E R 1 ) ,
ErB2 (neu/HER2), ErbB3 (HER3) and ErbB4 (HER4) [7,8].
All such proteins contain an extracellular domain respon-
sible for ligand binding, a single membrane-spanning
domain, and a cytoplasmic tyrosine kinase domain with
multiple auto-phosphorylation sites. Binding of a ligand to
EGFR leads to the formation of homo- or heterodimers,
followed by phosphorylation of tyrosine residues and
second messenger recruitment [7,8]. EGF is a potent
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any medium, provided the original work is properly cited.growth factor and one of the 11 ligands of this receptor
that signals via multiple downstream pathways including:
PI3K/AKT, ERK1/2, JNK, JAK/STAT3, and others,
dependent on which of the 5 tyrosine residues is phos-
phorylated [7].
EGFR signaling is critical for pancreatic development
and for b-cell proliferation, as shown by EGFR knock-
out and transgenic mouse models. Genetic disruption of
EGFR is lethal in the embryonic and peri-embryonic
periods and the pancreatic phenotype reveals a reduced
pancreas size due to impaired ductal branching, abnor-
mal islet cell localization, and defective differentiation
[9-12]. Embryonic cell cultures established from these
mice show a 50% reduction of b-cell mass, without
impairment of other islet cell types [9]. After birth,
tissue-specific attenuation of EGFR signaling in the
b-cell using a dominant negative EGFR (EGFR-DN) that
lacks 40% of tyrosine kinase activity leads to a failure of
postnatal b-cell proliferation and islet mass expansion,
resulting in insulin-deficient diabetes by two weeks of
life [13]. This suggests that EGFR signaling after birth is
critical for b-cell proliferation.
Survivin is the smallest member of a well-conserved
protein family known as inhibitor of apoptosis proteins
(IAPs) [14]. In cancer cells, survivin has at least two
established functions; one as an inhibitor of pro-
grammed cell death [15] and the other as a regulator of
cell division [16]. To perform its diverse functions, the
survivin protein must shuttle between multiple subcellu-
lar compartments, including the cytoplasm, mitochon-
dria, and nucleus [17]. Evidence suggests that survivin
can inhibit both the extrinsic and intrinsic (mitochon-
drial) pathways of programmed cell death by blocking
the activity of several caspase proteins [18,19]. Survivin
also forms a complex with a group of chromosomal pas-
senger proteins including Aurora B kinase, INCENP,
and Borealin [20,21] to regulate cell division. Phosphory-
lation of survivin at threonine 117 by Aurora-B regulates
survivin-targeting to the centromere and thus the entire
chromosomal passenger complex [22,23]. Phosphoryla-
tion at an additional site, threonine 34, is critical for the
anti-apoptotic function of survivin; whereby mutation at
this site results in caspase 3 activation and mitochon-
drial apoptosis [24].
During embryogenesis (E15.5) in the mouse, survivin is
expressed throughout the pancreatic epithelium [25].
Around the end of gestation, it becomes gradually
restricted to endocrine cells. Postnatally, its expression
becomes further restricted, where eventually (P21) it is
expressed exclusively within the pancreatic b-cells [25].
In previous work, we engineered mice harboring a condi-
tional deletion of survivin in pancreatic endocrine cells
by mating survivin floxed mice with mice expressing a
Cre-recombinase protein under the control of a Pax-6
promoter [25]. These mice developed insulin-deficient
diabetes after birth due to a failure of b-cell mass expan-
sion [25]. On a cellular level, we observed a slowing of
cell cycle progression through G1/S and G2/M in the
survivin null b-cells, which correlated with an increase in
expression of the cell cycle inhibitor, p21
WAF1. Similar
findings were also observed in a Pdx-1Cre;survivin
lox/lox
mouse model [26]. In other related work, transplantation
of pancreatic b-cells engineered to ectopically express
survivin from a rat-insulin promoter into streptozotocin-
treated mice resulted in long-term correction of hypergly-
cemia and rescue of streptozotocin-induced b-cell death
[27]. Together, these data suggest that survivin is impor-
tant in both the normal expansion of the b-cell
mass after birth and in the survival of b-cells following
stress-induced apoptosis.
As both EGF and survivin are essential for b-cell pro-
liferation, and as survivin expression is regulated by
EGF in cancer cells, we hypothesized that EGF also reg-
ulates survivin expression in b-cells and thereby is one
of the mechanisms involved in promoting b-cell growth.
We chose the well-established insulin-producing b-cell
lines, MIN6 and INS-1, as an experimental model sys-
tem to test this hypothesis. Here, we show that survivin
is regulated by several pancreatic b-cell growth factors,
including glucose, insulin, and EGF. Induction of survi-
vin by EGF occurs extremely quickly, within 15 minutes
of treatment. The mechanism of EGF-induced survivin
occurs primarily through activation of the ERK pathway
and prolongation of survivin half-life by inhibiting ubi-
quitin conjugation on the survivin protein. Thus, we
have identified a novel mechanism for survivin regula-
tion in pancreatic b-cells that implicates ERK as a criti-
cal molecule for its post-translational modification and
signaling for protein degradation.
Results
EGF regulates survivin protein expression in pancreatic b-
cells
To begin to understand the mitogenic responsiveness of
survivin in pancreatic b-cells we made use of the immorta-
lized mouse and rat b-cell lines, MIN6 and INS-1. MIN6
cells were cultured under proliferating conditions then
serum-and glucose-deprived for 2 to 4 hours, prior to
treatment for 30 minutes with glucose or insulin. Results
showed that varying concentrations of glucose (0 to
20 mM) or insulin (0 to 2000 nM) added to the cells can
induce survivin protein expression at these early time
points. MIN6 cells treated with glucose had a 10-fold
increase in survivin protein levels at a concentration of
≥ 5.5 mM (Fig. 1A). Cells treated with insulin at a concen-
tration of ≥ 20 nM had a similar increase in survivin levels
(Fig. 1B). As IGF-1 and EGF are both known to stimulate
survivin in cancer cells [28,29], we next tested whether
Wang et al. BMC Molecular Biology 2010, 11:66
http://www.biomedcentral.com/1471-2199/11/66
Page 2 of 9these growth factors can also induce survivin in pancreatic
b-cells. MIN6 and INS-1 cells were serum-deprived over-
night then treated with IGF-1 (100 ng/ml) or EGF (50 ng/
ml) for serial time points (0 to 360 minutes). EGF-treated
cells showed a five- to ten-fold increase in survivin protein
levels within 15 to 30 minutes after treatment (Figs. 1C
and 1D), with no differences observed following IGF-1
treatment (not shown). These early increases in protein
expression suggested that EGF likely regulates molecular
mechanisms that modify survivin protein stability, rather
than its transcription or translation.
As survivin is a multifunctional protein whose diverse
activities are carried out in different subcellular com-
partments [30], we next sought to gain insight into the
potential effects of EGF on survivin localization. To this
end, we performed indirect immunofluorescence stain-
ing using a survivin antibody in the presence or absence
of EGF, to visualize the endogenous survivin protein
within INS-1 cells, along with cell fractionation to quan-
tify survivin expression within these compartments. Sur-
vivin localized to both nuclear and cytoplasmic
compartments of untreated and EGF-treated cells, as
observed by indirect immunofluorescence (Fig. 2A). An
increase in both nuclear and cytoplasmic survivin
protein was observed by cell fractionation following EGF
treatment (Fig. 2B). These results suggest that EGF
stimulates both the anti-apoptotic and pro-mitotic func-
tions of survivin in pancreatic b-cells.
EGF regulates survivin through ERK activation
EGF signals through several downstream signaling path-
ways to induce b-cell growth, including PI3K/AKT,
E R K 1 / 2 ,J N Ka n dJ A K 2[ 7 , 8 ] .T od e t e r m i n ew h i c ho f
these pathways might be required for EGF-stimulated
survivin protein expression, we treated MIN6 and INS-1
cells with specific inhibitors of these pathways including:
LY 294002 (PI3K/AKT), UO126 (ERK1/2), SP600125
(JNK) and AG490 (JAK/STAT3). The EGF-stimulated
increase in survivin protein was only abrogated in the
presence of the ERK1/2 inhibitor (Fig. 3A and 3B), sug-
gesting that the ERK pathway is the primary signaling
pathway involved in EGF-mediated survivin regulation.
Interestingly, the response to the ERK inhibitor U0126
differed in the two cell lines. U0126 treatment of INS-1
cells blocked survivin induction within 15 to 30 minutes,
while treatment of MIN6 cells blocked survivin induc-
tion at later times (30 to 60 minutes) with a further
decrease in survivin observed at 180-360 minutes in
these cells. This suggests that there is a cell or species-
specific kinetics regulating the ERK-mediated increase in
survivin levels, in response to EGF.
EGF inhibits survivin protein degradation
To determine the biochemical mechanism of the
observed early increase in survivin protein levels follow-
ing EGF treatment in pancreatic b-cells, we first evalu-
ated potential changes in survivin mRNA and survivin
promoter activity. Serum-deprived INS-1 cells were trea-
t e dw i t hE G F( 1 0 0n g / m l )f o r0 . 5 ,1 ,2 ,a n d4h o u r s
prior to harvesting RNA for quantitative RT-PCR. No
significant changes in survivin mRNA were observed at
any of these time points (Fig. 4A), suggesting that EGF
does not likely regulate survivin transcription in INS-1
cells. To validate this finding in primary islet cells, we
Figure 1 Glucose, insulin, and EGF induce survivin protein expression. MIN6 and INS-1 cells were serum-deprived for 2 to 4 hours (A and B)
or overnight (C and D) then glucose, insulin, or EGF (50 ng/ml) were added at the indicated concentrations and times. (A) Survivin protein levels
in response to glucose in MIN6 cells. (B) Survivin protein levels in response to insulin in MIN6 cells. (C) Survivin protein levels in response to EGF
in INS-1 cells. (D) Survivin protein levels in response to EGF in MIN6 cells.
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s t a r v e dt h e mo v e r n i g h tt h e ni n c u b a t e dt h e mw i t hE G F
(100 ng/ml) for 2 hours. Following mRNA preparation,
we performed quantitativeR T - P C Ru s i n gp r i m e r st o
detect total mouse survivin and three mouse survivin
splice forms, survivin 121, survivin 140 and survivin 40
[31]. No significant increases in survivin mRNA follow-
ing EGF treatment were observed in the primary islets
(Fig. 4B), similar to the results obtained in the INS-1
cells. To examine whether this observation correlated
with a lack of stimulation of survivin promoter activity,
we transfected MIN6 cells with luciferase reporter con-
structs containing different regions of the survivin pro-
moter, from 400 to 6000 bp upstream of the survivin
ATG start site [32]. Twenty-four hours after transfec-
tion, cells were serum-deprived overnight then treated
Figure 2 EGF enhances nuclear and cytoplasmic survivin protein levels. INS-1 cells were serum-deprived overnight then treated with or
without EGF for 4 hours. (A) Cells were fixed and immunostained with a survivin antibody, stained with DAPI (DNA detection) then analyzed by
Z-stack confocal microscopy. (B) Nuclear and cytoplasmic protein fractions were prepared, resolved by SDS-PAGE then transferred to PVDF
membranes and immunoblotted with anti-survivin, anti-actin, and anti-HDAC1.
Figure 3 EGF induces survivin through ERK activation. INS-1 (A) and MIN6 (B) cells were serum-deprived overnight then treated with
inhibitors to ERK1/2 (U0126), PI3/AKT (LY294002), STAT3 (AG490), and JNK (SP600125) for 30 minutes prior to the addition of EGF. Proteins were
harvested at the indicated times for Western blot analysis and immunoblotted with anti-survivin, anti-actin, and anti-phosphorylated-ERK (p-ERK).
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differences in reporter levels between EGF-treated and
u n t r e a t e dc e l l sw e r eo b s e r v e d( F i g .4 Ca n dd a t an o t
shown), indicating an absence of EGF-stimulated tran-
scriptional regulation sites within the survivin promoter.
As no significant increases in survivin mRNA or its
promoter activity were observed following EGF
treatment, we hypothesized that EGF was acting at a
post-transcriptional level to either increase ribosomal-
mediated protein synthesis or to inhibit protein degrada-
tion. To test these possibilities, we treated INS-1 cells
with the protein synthesis inhibitor, cyclohexamide
(CTX). Cells were serum-deprived overnight then trea-
ted with EGF. CTX was added for 0 to 90 minutes prior
to cell collection at four hours post EGF treatment. In
control cells, a decrease in survivin protein levels was
observed within 30 minutes, in agreement with pub-
lished results of survivin protein half-life [33] however,
in EGF-treated cells no significant decrease in protein
levels was observed until 90 minutes after CTX treat-
ment (Fig. 4D). This supports the hypothesis that EGF
can inhibit survivin degradation to prolong the survivin
half-life.
Degradation of survivin protein normally occurs
through activation of the ubiquitin-proteasome pathway
[34]. To investigate whether EGF might protect survivin
from degradation by inhibiting this pathway, we treated
INS-1 cells with the 26 S proteasome inhibitor, MG132
[35]. Lysates were immunoprecipitated with a survivin
antibody or immunoglobulin control antibody then
immunoblotted with anti-survivin or anti-ubiquitin.
Results showed an increase in total survivin protein
levels, both in the presence of the proteasome inhibitor
and following EGF treatment (Fig. 4E). Treatment with
MG132 also led to an accumulation of the ubiquitinated
form of survivin, as expected from the results of prior
studies showing that survivin is degraded via this path-
way [33,34]. By contrast, EGF treatment resulted in a
decrease in ubiquitinated-survivin (Fig. 4E), suggesting
that EGF inhibits conjugation of ubiquitin on the survi-
vin protein, prior to proteolytic activation of the 26 S
proteasome.
Figure 4 EGF inhibits survivin protein degradation by blocking survivin ubiquitination. (A) INS-1 cells were starved overnight then treated
with or without EGF for serial time points, as indicated. Survivin mRNA levels in the presence of EGF were compared to those in the absence of
EGF, as performed by quantitative RT-PCR (qRT-PCR). The relative levels and standard error (SE) of triplicate experiments are shown. (B) Primary
mouse islets were starved overnight then treated with or without EGF for 2 hours. qRT-PCR was performed for all the mouse survivin splice
forms (survivin 121, 140, and 40). Bars represent the relative levels of duplicate experiments. (C) MIN6 cells were transfected with a survivin
promoter construct regulating luciferase (luc-6000) or control plasmid (EV). Reporter activity was measured after overnight serum-deprivation and
2 hour EGF treatment. The mean and SE of triplicate experiments is shown. (D) INS-1 cells were starved overnight then treated with EGF for 4
hours. CTX (100 mg/ml) was added at the indicated times prior to the completion of the EGF treatment and protein harvested for Western blot
analysis. (E) INS-1 cells were starved overnight then treated with the proteasome inhibitor MG132 for 3 hours followed by EGF for 1 hour. Lysates
were harvested and immunoprecipitated with anti-survivin or immunoglobulin (Ig) control, resolved by SDS-PAGE, transferred to PVDF
membranes and immunoblotted with anti-survivin or anti-ubiquitin (pan-Ub).
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During late embryogenesis and immediately after birth,
a transient burst of replication of pancreatic b-cells
occurs with a consequent marked increase in b-cell
growth [1,2]. New b-cells continue to form in the adult
animal as well, primarily from the replication of mature
b-cells [36]. This replication mechanism also appears to
be of primary importance in humans, with the highest
rates occurring within the first year of life [37]. Our pre-
vious data showed that mice lacking survivin within
pancreatic b-cells develop insulin-deficient diabetes and
are unable to expand their b-cell mass after birth. This
phenomenon is due primarily to an inhibition of cell
cycle progression [25], suggesting that the predominant
effect of survivin in b-cells is to induce postnatal prolif-
eration. Here, we aimed to examine the potential factors
upstream of survivin that might regulate survivin
expression in b-cells. As EGF-ligand activation of the
EGFR receptor is important for maintaining b-cell mass
as well as for b-cell function [8], and as it is known to
regulate survivin transcription in cancer cells [29], we
hypothesized that it might also regulate survivin in b-
cells during periods of active replication. In this report,
we demonstrate that survivin protein expression is
enhanced at early time points following treatment with
critical b-cell growth factors including glucose, insulin,
and EGF. The molecular mechanism of the EGF-
mediated increase in protein expression primarily
involves activation of the ERK signaling pathway.
EGFR signaling leads to the activation of several
downstream cascades, with the two major pathways
including PI3-kinase/AKT and Ras/Raf-1/ERK [38].
Although much of the work studying these pathways
has been performed in cancer cells, it has recently
been demonstrated that endogenous Raf-1 signaling is
required to suppress basal b-cell apoptosis [39] and
that Raf-1 also participates in b-cell proliferation
[40,41]. Further, low concentrations of insulin (0.2-
20 nM) rescued human and rodent islets from serum
withdrawal-induced apoptosis through Raf-1 activation
[42,43] and islets isolated from mice with a 50% reduc-
tion in glucose-stimulated insulin secretion had a 50%
loss of ERK activation in response to glucose [44]. Glu-
cose and insulin stimulate nuclear translocation of
ERK, an event that has been proposed to promote
b- c e l ls u r v i v a la n dg r o w t hv i aE R K - d e p e n d e n t
transcription [44]. Our finding that EGF-mediated
signaling through the Raf-1/ERK pathway prolongs the
survivin protein half-life suggests another mechanism
by which ERK signaling may promote the survival and
growth of pancreatic b-cells.
The EGF-dependent early increase in survivin protein
is not significantly regulated at the level of transcription,
as there is no significant EGF-dependent increase in sur-
vivin mRNA observed during these early time periods,
nor is the survivin promoter activated. By contrast,
experiments conducted in the presence of the protein
synthesis inhibitor cyclohexamide support a post-trans-
lational mechanism of EGF-dependent regulation, with a
decrease in protein degradation rate observed in the
presence of EGF. In contrast to the 30 minute half-life
of survivin in the absence of EGF, the survivin half-life
is increased to 90 minutes in the presence of EGF.
The ubiquitin-proteosome pathway plays a central
role in the regulation of multiple proteins involved in
cellular homeostasis [45]. Many short-lived, key regula-
tor proteins including the cyclins (cyclin A, B, D, E),
cyclin kinase inhibitors CKI (p21, p27, p57), and tran-
scription factors are regulated by this pathway [46]. Ubi-
quitin-proteasomes also regulate programmed
proteolysis of pro- and anti-apoptotic proteins, includ-
ing Bcl-2 family proteins and IAPs [46]. Previous work
demonstrated that the ubiquitin-proteasome pathway
regulates survivin degradation in a cell cycle-dependent
manner [33]. Deubiquitination of survivin is also
required for the proper targeting of survivin and its
partner chromosomal passenger proteins to centromeres
[34], enabling accurate cell division to take place. Our
data suggest that EGF can inhibit ubiquitination of sur-
vivin in pancreatic b-cells, thereby prolonging its pro-
tein half-life.
EGF is currently in human clinical trials to treat insu-
lin-deficient diabetes (Transition Therapeutics, Inc),
with preliminary results showing a decrease in exogen-
ous insulin requirements. It is unclear if this observed
effect is due to improved b-cell function or to increases
in b-cell proliferation of the remaining b-cells. Our
results show that EGF enhances survivin stability
through activation of the Raf-1/ERK pathway in the
pancreatic b-cell lines MIN6 and INS-1 and support
future work in exploring this pathway in vivo.
Methods
Cell culture
MIN6 (early passage, < 30) and INS-1 cells (line 832/
13, passage < 25) were grown under proliferating
conditions in DMEM/10% FBS. Cells were serum-
deprived overnight prior to the addition of EGF (50 -
100 ng/ml) or IGF-1 (100 ng/ml) for 2 to 4 hours
prior to adding glucose or insulin. To inhibit the EGF
signaling pathways, cells were treated with the follow-
ing compounds: LY 249002 (50 μM), UO126 (10 μM),
SP600125 (20 μM) and AG490 (50 μM) (EMD
Biosciences, San Diego CA) 30 minutes prior to EGF
treatment then harvested for Western blot at the times
indicated.
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Pancreatic islets were isolated from 8-week old C57/Bl6
mice, as described previously [47]. The islets were sepa-
rated by gradient centrifugation with Histopaque 1077
(Sigma) then handpicked under a dissection microscope
and recovered in RPMI1640 media containing 10% FBS
overnight. The following day, 100 to 500 islets were
placed in 35 mm dishes containing RPMI1640 media
without FBS. After overnight starvation, islets were trea-
ted for 2 h with EGF (100 ng/ml) then harvested for
RNA. These experiments were approved by the Institu-
tional Animal Care Board (IACUC) at Rhode Island
Hospital.
Western blotting and immunoprecipitation
Whole cell lysates were collected in RIPA buffer for
Western blot analyses. 50 μg of protein per lane was
separated on a 12-15% SDS-PAGE. Gels were trans-
ferred to nitrocellulose membranes then blotted with a
rabbit anti-survivin antibody (Santa Cruz Biotechnology
sc-10811, 1:1000) in 5% non-fat dry milk (NFDM), fol-
lowed by anti-rabbit antibody (GE healthcare # NA934,
1:2000). Nuclear extracts from INS-1 cells were pre-
pared according to the method of Schreiber et al.[48].
Total protein concentration was measured using BCA
protein assay kit (Thermo Scientific) against a bovine
serum albumin standard curve. Cells were collected,
washed with PBS twice and pelleted by centrifugation.
The cell pellet was resuspended in 50 μlc o l db u f f e rA
( 1 0m MT r i sp H7 . 5 ;1 0m MK C l ;0 . 1m ME G T A ;1 %
NP-40; 1 mM DTT; 1 mM PMSF; 1 complete Mini
tablet) vortexed for 10 sec, then shaken on a rocker vig-
o r o u s l yf o r1 0 - 1 5m i n .T h el y s a t ew a sc e n t r i f u g e da t
13000 RPM for 10-15 min. The supernatant containing
cytoplasm was transferred to a fresh tube. The nuclear
pellet was resuspended in 50 μl ice-cold buffer C
(20 mM Tris pH 7.9; 400 mM NaCl; .5 mM EGTA; 1.5
mM MgCl2; 25% Glycerol; 1 mM DTT; 1 mM PMSF)
and the tube vigorously rocked at 4°C for 15 min on a
shaking platform. The nuclear extract was centrifuged
for 10 min at 13000 RPM at 4°C and the supernatant
(nuclear extract) transferred to a new tube. Nuclear or
cytoplasmic fractions were resolved by SDS-PAGE.
PVDF membranes were probed with mouse anti-survi-
vin (Santa Cruz Biotechnology, sc-17779, 1:1000), rabbit
anti-HDAC1(Affinity Bioreagents, #PA1-860, 1:5000) or
mouse anti-Actin (Santa Cruz Biotechnology, sc-47778,
1:1000).
For the ubiquitin experiments, INS-1 cells were pre-
treated with MG132 (10 uM) for 3 h before being trea-
ted with EGF (100 ng/mL) for 1 h. Lysates were
precleared with 15 μl of Protein A/G PLUS-Agarose
(Santa Cruz Biotechnology, sc-2003) for 1 h prior to
overnight incubation with 1 μg of either normal rabbit
IgG (Santa Cruz Biotechnology, sc-2027) or rabbit poly-
clonal Survivin (Santa Cruz Biotechnology, sc-10811)
primary antibody. 30 μl of Protein A/G Plus-Agarose
beads were then added to form immunocomplexes and
samples were shaken for 2 h. Samples were then spun at
3000 RPM for 5 min. Supernatant was discarded and
Protein A/G Plus-Agarose beads were washed 4 times
and then resuspended and boiled in a SDS loading buf-
fer. All previous steps are performed at 4°C unless
otherwise noted. Immunocomplexes were resolved by
SDS-PAGE. PVDF membranes were probed with mouse
anti-survivin (Santa Cruz Biotechnology, sc-17779) or
rabbit anti-ubiquitin (Cell Signaling, #3933 S, 1:1000).
Cyclohexamide treatment
INS-1 cells were starved overnight then treated with or
without EGF (100 ng/ml) for a total of four hours. CTX
(Calbiochem # 239765 100 mg/ml) was added 1.5 h
prior to the completion of the four-hour EGF treatment.
Analysis of mRNA expression
INS-1 and primary islet cells were harvested for RNA
using the Qiagen RNAeasy kit (Qiagen Inc, Valencia
CA). RNA was reverse transcribed into cDNA using
Omniscript reverse transcriptase (Qiagen Inc, Valencia
CA). qRT-PCR for survivin and gapdh were performed
using the SYBR Green Master Mix kit from Applied
Biosystems (Applied Biosystems Inc, Foster City, CA).
Primers for total mouse survivin were as follows: For-
ward-Primer GATCTGGCAGCTGTACCTCA; Reverse-
Primer ATTGACTGACGGGTAGTCTTTG. Primers for
full-length rat survivin were as follows: Forward-Primer
5′ CCGATCTGGCAGATGTACCT, Reverse-Primer 5′
AGGGGAGTGCTTCCTATGCT. Survivin expression
levels in the presence of EGF, relative to those in the
absence of EGF were calculated using the ΔΔCT
method in comparison to the housekeeping gene
GAPDH. Experiments were performed in triplicate (INS-
1 cells) or duplicate (primary islets).
Luciferase assays
Promoter pGL2-enhancer constructs containing DNA
varying in length from 400 to 6000 bp upstream of the
survivin transcription start-site were a kind gift of Drs.
Hatono and Tokuhisa [32]. The upstream DNA segments
were removed from the pGL2-enhancer vector and
ligated upstream of the luciferase reporter in the
pGL4.10[luc2] (Promega Corp., Madison WI) vector
without additional enhancer elements. Plasmids were
transfected into MIN6 cells, serum deprived overnight
then treated with EGF (100 ng/ml) for 2 h. Luciferase
reporter activity was measured using the Promega Dual
Glo kit (Promega Corp., Madison WI). Experiments were
performed in triplicate.
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INS-1 cells were grown to approximately 50% conflu-
ence in an 8 chambered glass slide, serum-starved and
treated with EGF as above. Cells were fixed in 3.7% for-
maldehyde, 0.2% TritonX-100/PBS for 15 minutes at
room temperature. Blocking was done in 1% BSA, 5%
NGS/PBS for 1 hour. Primary antibody was rabbit anti-
survivin (FL-142, Santa Cruz Biotechnology, CA). Sec-
ondary antibody was anti-rabbit IgG conjugated to
Dylight 488 (ThermoFisher Scientific, Waltham MA).
The slide was mounted with Prolong anti-fade reagent
(Life Technologies, CA). Images were captured using a
Nikon C1si Confocal microscope.
Abbreviations
EGF: epidermal growth factor; IGF-1: insulin-like growth factor; CTX:
cyclohexamide; IP: immunoprecipitation.
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